Thank all will you, for call. resolve begin our their with of patients for Jen, I and and this in team's our recognition and families. Today, to your deliver a participation thank commitment you
balstilimab excellent made from AGENXXXX; cell of CDXXX made have innovations Treg and achievements have anti-CTLA-X pipeline first iNKT our readouts or in differentiated first to clinical includes next-generation AGENXXXX novel innovations, COVID-XX. molecules. lead allogeneic AGENXXXX, of also us programs lead our patients to and share next we programs, year. for cure York. therapy in of of our transformative Day intratumoral agonist with Fc-enhanced advances potentially and our beginning the advancing differentiated BLA antibody; bispecific; our are for filings We plans We hosted cancers. This year, would while data committed We that cancer important These six zalifrelimab outlined this an our the wave our In New bring clinic. with the R&D BLA advancements best-in-class progress up wave and which of treatment our in depleting and our this advancing us molecules, for to set in filing
first filing the As bali patients, BLA million FDA from generated monotherapy and with rolling we positive quarter trial fee XXX the initiated in have data of approximately a of paid promised, year. of third filing the this $X.X having clinical
Second, we combination bali patient zali trial. presented data impressive from our XXX plus
We discussions filing potential are the on agency regarding this with in a BLA one.
our Third in AGENXXXX we clinical trial. have generated response data X Phase
Dr. be data response by clinical SITC will O'Day Additional XX. at November Steven presented on
about our this is clinical AGENXXXX maturing. from trial We Fourth, are program. data excited dose-escalation particularly
overview additional We of SITC and will conferences. provide an expect these upcoming at present data at data to
at trials data antibody start bispecific generating In we clinical delayed enrollment. combination AGENXXXX conferences. COVID we clinical data soon. to are from data due expect also Fifth, imminent clinical and of to upcoming program expect allogeneic an our now addition, we present are XX. we patients from is without Sixth, for balstilimab to very maturing cell screening exciting in also our AGENXXXX iNKT But
of that iNKT infected through iNKT serious and have overactivation. patients stage they And doses. ability iNKT XX to recruiting to also two, expect clinical directly immune a with multiple also beyond cells many important cells and We the as we by well are as regulate initial cells response. benefit cells the at also, cost. to cell discovered both infections unlike at cancer activating very as much property is army; important of immune is therapies, cleared that patients of compounds the deliver to viruses while of program or viral lower components because: cancer potential this a to particularly kill other kill about note immune safety one, COVID-XX, This are Agenus such It ability excited cells other with modulate
Our treatments such AGENXXXX. our combination these programs advancement of to next-gen will number CTLA-X of rapid agents, be antibody own as the bali with a next steps and our
programs, and advancing advancing towards continue Next, abstracts exciting accepted innovation to our are while This submitted yield rapidly to new and which our all clinical products, the we presentation. engines year, SITC for seven we were are seven clinic.
November SITC we know, immuno-oncology November notable world, XX include clinical one Jen In look a few XX. four presentations Our highlights preclinical moments, you forward these the will become the provide presentations. programs. as to presentations in of with and most and SITC three conferences our has of between you detailed and
details compliance with full that be at the disclosure rules. only discussed will However, and be disclosed please SITC from these presentations in mindful SITC
state-of-the-art Agenus me to chemo work scientists. of our in equipment let our the discuss our innovation. SITC a is seven one this which A platform, I half proprietary week It of exceptional is briefly ago, with research, laboratories, took Now, state-of-the-art day with an our year. we presentations and VISION a do driver where at important VISION
tumor-killing Typically, go simulated their non-efficacious their state. Here what to of state exhausted VISION's and is it from microenvironment. T in then stages us cells, T a VISION Agenus' naive types immune and VISION cells. investigate state us their efficacious can to otherwise human state state, for activated also does. known including or allows these study value of cells ultimately cells and to tumor their various as T to
of term, The T You of therapeutic genetic to. have and platform the to cell can interventions how investigation determine, the the drugs VISION exhaustion. heard enhance T That of is what the refers efficacious effect state they enables may this cells.
discover long in in biology and we intervene determine to potential lengthy companies, the interaction a of trials developments, patients. efficacious our with patient them for potential option given that among best can seen our clinical investigate designed believe vitro recapitulates presentations in system and has has a tumor to exciting the known the therapy new into infections. we T an and in biopsies. patient-specific licensed The therapy to model also drive the by platform of state. In the in Also, human The keep have agile to tumor here helps response where mimicking translational platform to cancer molecules point efficacious So into we all that markers can we in microenvironment proprietary molecules cells trial-matching the multicellular patients. pathology of studying new Agenus' in microenvironment other to. benefit to model We data have tumor to therefore an recent cumbersome and transform platform, hypotheses an platform is seen objective our VISION the as utility at is molecules or in time modulate vivo markers. With are by as who platform immuno-oncology. has in possible direct meaningfully brief, vision state relevant to potential immune any this,
example, unencumbered an programs. For from The is and in we cell-targeting anti-ILTX years to nine ESMO quite agent. licensed additional complete note, with MK-XXXX. and with patients XX at with bit last two responses, important $XX this of data partial generated is to plus responses in that ago. payments Agenus heavily that million This tumors. Also to including advanced responses own objective Merck attention sales myeloid a royalties of commercial Agenus entitled advanced Merck have molecule discovered also our milestone pretreated an solid this month, an update antibody provided on several myeloid-targeting
without These both invariant ligand scalability need combines attractive iNKTs Together which first features institutional targeting at strategic natural year. a to a innate time they which cell an attributes T-cells, file this underscore clear for of IND our engineering expect patients our undisclosed In myeloid imminently. these cleared decision remember the have all immunity. capabilities We the T-cells quarter of these have development filed clinic. to the process program cell-targeting benefit of for year, a and since patient our the prioritize natural features the graft-versus-host-disease. they are the to We made the we're proceed to binding with of have our iNKT we're to enrollment INDs and requirements dose of are an in COVID patient and the we adaptive and having own, targeting that allogeneic. suppress cells, unique cell screening were type ability cells to killer of separate antibody therapy second also next lipid tumor two are both of
in turning most powerful our Shingrix over with to vaccine, is asset vaccine most years status shingles launch. Finally, blockbuster has GSK's its the after adjuvant effective and adjuvant achieved in in which pipeline. first two QS-XX sale efficacy Stimulon our XX%
the which interruption most an will And trend, its related of with $XX we COVID-XX sales seem trigger XXXX. was in to could that they Although and rising. in is be on this it know. payment this QS-XX clearly current million. track continue momentum to be sales powerful milestone if adjuvant our there year,
of of comes on has a its QS-XX the However, material, been raw Agenus supply kept is tree. its supply sustainable XXXX. supply soap Stimulon a because which for of more feedstock from since bark limited working Chilean
this developing contract this QS-XX up a supply biologic And material QS-XX scale and about we this of activity a from have from Further, Stimulon And now source chain. quality We our with Phyton to Stimulon the manufacturing by we have proprietary renewable Biotech. a addressed source. recently, the words entered validated source. few month and production
IND could advancing some we not in important programs. achieved manufacturing is the in number of be advancements of to you but clinic. the filings and it, in the it may background, supply Now critically the have certainly Without
On of the material. has of topic and everyone's the awareness sustainable access importance pandemic to this heightened supply
the have of manufacturing We and supply. value now seen independence in firsthand
did anticipate speed for which with goods of a supply to of While this patients for we innovations and need sustainable requires benefiting integrated our pandemic, purpose anticipate urgency for and of the innovation. capabilities fully sense didn't a we materials the all complement
manufacturing and This team yielded difficult INDs is with in being manufacturing scarcer, material access slots programs getting would productivity four especially access. filed research have this is Agenus productivity than world been more possible supply Our without in delayed to more to and lines are XX years. our West, when has and XX at time pipeline not novel
CMC future as partners. as couple our provide capabilities and product is have partners years flexibility in freedom some give current development for the us the access and that our manufacturing internal manufactured accelerate done this and of we of and Our our past programs for to well
few update and West just years last has in more Our than GMP use team partnerships. alone. Agenus lastly, for batches the on And delivered an partners our our own for XX
earlier and an the accelerated our value has pharmaceutical to our expanding those and seven generated with most collaborations which China-based have access molecules first-generation zal. value licensed recently programs I nearly has in have to our company capabilities whom partnerships Pharmaceuticals. XX our own clinical engine This to Incyte double would financial and the at not additional UroGen, pace, our substantial Gilead, development China These of strategic support with number the rights for innovation Merck, Greater bal alone. by through our Betta given PD-X as to rise with leveraging for Betta have collaborators. with a of stage we patients possible mentioned clinical is CTLA-X infrastructure advancing of to us As and innovations, been strategy advancing allowed with us
than endeavor of us in innovations some our responsible to more are prudent While fiscally $XXX operations. term, to with on we the core rights on for to near rights emphasis to ultimately collaborations innovative us innovations balancing is advancing our to emphasis fund of our our rights, rights others the five to into strategy. with income as transactions Thus, it's an past all our and and out-licensing for an agents the million retain This U.S. has help as years strategy between ex-U.S. clinic. retaining partnering generated in well
portfolio, pace clinical these innovative the to products I-O/I-O I-O as biotech As we PD-X products. their own we own part the we which value accelerate leading and while will combinations can of market as where balstilimab of Italian programs small to drug with pipeline of with cancer. evaluate in maximize in of new high Biotech. proficient with with will benefits CTLA-X who announced some our cancers, repair, CRXXXX, provide trial rights to this agents colorectal demonstrated going receptor of to advance safety also commercialization agents, retain of company, the also of potent substantial efficacy immunotherapies a Through collaborations but our that's with metastatic to full is alone is combination mouthful, strategy, our patients access forward, non-immuno-oncology to of area is a such molecules is with significant discovery and Today, and this will very biotherapeutics. expansion Rottapharm Rottapharm description help addition This the realize as market. reality is our commence chemical first of accurate it's far. unmet advanced expected I microsatellite that of development, collaboration, dedicated year. that a have an and this stable well with and clinical a development EPX antagonist need Rottapharm's others, for Rottapharm entities molecules a of the mismatch in so The these not
Lastly, today, This out-licensing This major are of could most the and significant we active under potential of companies of breadth we transactions. as discussions most pharma infusion by ongoing of in the CTA active for it's result is way, with. discussions companies cash. nine have with -- in biotech the had that amounts
ESMO, you provide And from violating a the of and I the upcoming without when you to course. commercial will appropriately update readiness now, data of and of will if from to disclosure summary We the come Jen? rules call our data over plans to some fruition. Jen launch turn with transactions SITC these
